Join us in our daily reports from the AACR Annual Meeting 2018
Supported by an unrestricted educational grant from:
An immunotherapy treatment combining the IDO1 inhibitor epacadostat and the PD-L1 inhibitor durvalumab was found to be safe in patients with advanced solid tumors.
TLR9 agonist CMP-001-pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1.
Neoadjuvant nivolumab was safe, and yielded pathologic responses in patients with resectable lung cancer.
KEYNOTE-189 met its dual primary endpoints of overall survival and progression-free survival in newly diagnosed metastatic NSCLC.
Patients with newly diagnosed advanced NSCLC with high tumor mutational burden had significantly improved PFS with nivolumab plus ipilimumab.
In the KEYNOTE-054/EORTC 1325 MG-trial, patients randomized to pembrolizumab were 43 percent less likely to have recurrence.
Despite efforts to amplify tumor-specific T-cell response, no meaningful antitumor activity was yet observed. New technologies show promise of an individual treatment option.
The results of the placebo controlled double blind phase III study Keynote 054 will be presented at the AACR annual meeting.
Combinations of immune checkpoint inhibitors and chemotherapy show promising results. Results of the the KEYNOE 189 study will be presented at the AACR.
Immune checkpoint inhibitors show promise in the treatment of rare mCRC cases with high microsatellite instability.
Mit einer Anmeldung bei medonline haben Sie Zugriff auf Fortbildungen, Arzneimittelinfos, Produktfortbildungen und mehr. Registrieren Sie sich kostenlos auf medonline. Registrieren
...so that we can improve our services for you. Your data will be evaluated anonymously.